Grifols (GRFS) Projected to Post Quarterly Earnings on Wednesday

Grifols (NASDAQ:GRFS) is expected to be issuing its quarterly earnings data on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $1.86 billion for the quarter.

Grifols Stock Performance

GRFS stock opened at $7.45 on Monday. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols has a twelve month low of $5.30 and a twelve month high of $9.96. The business’s fifty day moving average is $7.38 and its 200-day moving average is $8.09.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on GRFS shares. Morgan Stanley began coverage on Grifols in a research report on Wednesday, February 12th. They set an “overweight” rating for the company. Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.